Company Profile

Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company's commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.

Employees

Sector

Healthcare Facilities & Services

More about the company

26/07/18	Summit Resources Inc cancelled the acquisition of all assets of Protea Biosciences Group, Inc (OTCPK:PRGB.Q).	CI
02/02/18	Protea Biosciences, Inc. Emerged from Bankruptcy	CI
26/01/18	Motion for Asset Sale Approved for Protea Biosciences, Inc.	CI
19/01/18	Final DIP Financing Approved for Protea Biosciences, Inc.	CI
13/12/17	Bidding Procedure Approved for Protea Biosciences, Inc.	CI
12/12/17	Interim DIP Financing Approved for Protea Biosciences, Inc.	CI
05/12/17	Protea Biosciences Group, Inc Announces the Resignation of David Halverson as President	CI
05/12/17	Motion for Asset Sale Filed by Protea Biosciences, Inc.	CI
05/12/17	Motion for Joint Administration Approved for Protea Biosciences, Inc.	CI
05/12/17	Summit Resources Inc entered into asset purchase agreement to acquire all assets of Protea Biosciences Group, Inc (OTCPK:PRGB.Q) for $1.3 million.	CI
02/12/17	Protea Biosciences, Inc. Announces Resignation of Patrick Gallagher as Member of the Board	CI
01/12/17	Motion for Joint Administration Filed by Protea Biosciences, Inc.	CI
01/12/17	Protea Biosciences, Inc. Filed for Bankruptcy	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROTEA BIOSCIENCES GROUP, INC	-.--%	-.--%	-	-	803
NATERA, INC.	-0.21%	+8.19%	+95.99%	+438.26%	39.41B
LABCORP HOLDINGS INC.	+0.52%	+2.22%	+19.16%	+45.87%	25.27B
SONIC HEALTHCARE LIMITED	-0.70%	-1.80%	-20.89%	-35.11%	7.68B
RADNET, INC.	-3.12%	+5.82%	+20.92%	+101.99%	5.44B
DR. LAL PATHLABS LIMITED	-0.12%	+0.24%	+18.15%	+60.61%	3.32B
GENEDX HOLDINGS CORP.	-1.40%	+9.77%	-34.45%	+879.13%	2.11B
NEOGENOMICS, INC.	-3.44%	+3.01%	+179.89%	-1.19%	2.09B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+0.54%	+1.39%	-9.53%	-59.36%	1.9B
DIAN DIAGNOSTICS GROUP CO.,LTD.	+7.57%	+17.63%	+22.29%	-14.98%	1.66B
Average	-0.04%	+6.81%	+32.39%	+157.25%	9.88B
Weighted average by Cap.	-0.16%	+5.80%	+51.79%	+232.18%

Protea Biosciences Group, Inc Stock

Stocks

Healthcare Facilities & Services

Latest news : Protea Biosciences Group, Inc

Medical & Diagnostic Laboratories

Company Profile